In a xenograft model of mouse pancreatic cancer, a type I PRMT inhibitor combined with PD-L1 blockade demonstrated anti-tumor effect through increasing infiltration of CD8 + T cells [111]. The gene discussed is CD8A; the disease is neoplasm.